Part of the [C]LSDF ongoing series Watching the Bio IPO Market. Talecris Biotherapeutics (NASDAQ: TLCR) made a thunderous debut with its Initial Public Offering on the Nasdaq today, offering 50,000,000 shares at $19 and raising $950M in the process. The fun however, did not stop there as the third life science offering of the year [...]

• 449http://clsdf.com/2009/10/talecris-and-then-there-were-three/Talecris+%7C+And+Then+There+Were+Three%212009-10-02+02%3A06%3A00admin

The Rocky Mountain Life Science Investor Conference yielded a sense of sophistication and intensity catalyzed by the aggregation of high-quality presenting companies and top-tier venture and corporate investors. I was hardly surprised that then rumor, hearsay and innuendo combined to yield quite a bit of buzz throughout the oak paneled hallways of the Ritz Carlton [...]

• 448http://clsdf.com/2009/10/tape-delay-from-the-rmlsic-that%e2%80%99s-a-wrap/Tape-Delay+from+the+RMLSIC+%7C+That%E2%80%99s+a+Wrap%212009-10-01+13%3A55%3A00admin